Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study

Thrombosis Research

Volumn 135, Issue 6, 2015, Pages 1110-1116

  Ashrani, Aneel A ^a   Barsoum, Michel K ^a   Crusan, Daniel J ^a   Petterson, Tanya M ^a   Bailey, Kent R ^a   Heit, John A ^a  

^a Department of Health Sciences Research   (United States)

Author keywords

Epidemiology; Hydroxymethylglutaryl CoA Reductase Inhibitors; Hypolipidemic Agents; Pulmonary Embolism; Venous thromboembolism; Venous Thrombosis

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; ANGINA PECTORIS; ARTICLE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PARESIS; PERIPHERAL VASCULAR DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; VARICOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ADOLESCENT; AGED; BLOOD; COMPLICATION; CORONARY DISEASE; HYPERLIPIDEMIAS; LONGITUDINAL STUDY; MIDDLE AGED; ODDS RATIO; PULMONARY EMBOLISM; STATISTICAL MODEL; VENOUS THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84929501809     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.005     Document Type: Article

References (74)

1. E. Falk, and V. Fuster Atherothrombosis: Disease burden, activity, and vulnerability V. Fuster, R.A. Walsh, R.A. Harrington, Hurst's The Heart 13th ed. 2011 McGraw-Hill New York 1215 1223
2. T. Kawasaki, J. Kambayashi, H. Ariyoshi, M. Sakon, E. Suehisa, and M. Monden Hypercholesterolemia as a risk factor for deep-vein thrombosis Thromb Res 88 1 1997 67 73
3. J.H. Griffin, J.A. Fernandez, and H. Deguchi Plasma lipoproteins, hemostasis and thrombosis Thromb Haemost 86 1 2001 386 394
4. A. Vaya, Y. Mira, F. Ferrando, M. Contreras, A. Estelles, and F. Espana Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors Br J Haematol 118 1 2002 255 259
5. S.Z. Goldhaber, F. Grodstein, M.J. Stampfer, J.E. Manson, G.A. Colditz, and F.E. Speizer A prospective study of risk factors for pulmonary embolism in women JAMA 277 8 1997 642 645
6. A.W. Tsai, M. Cushman, W.D. Rosamond, S.R. Heckbert, J.F. Polak, and A.R. Folsom Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology Arch Intern Med 162 10 2002 1182 1189
7. B. Linnemann, D. Zgouras, M. Schindewolf, J. Schwonberg, M. Jarosch-Preusche, and E. Lindhoff-Last Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry Blood Coagul Fibrinolysis 19 2 2008 159 165
8. A.G. Holst, G. Jensen, and E. Prescott Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study Circulation 121 17 2010 1896 1903
9. F.H. de Man, R. Nieuwland, A. van der Laarse, F. Romijn, A.H. Smelt, and J.A. Gevers Leuven Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy Atherosclerosis 152 2 2000 407 414
10. R. Pathansali, N. Smith, and P. Bath Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia Platelets 12 5 2001 292 297
11. N. Sattar, J.R. Petrie, and A.J. Jaap The atherogenic lipoprotein phenotype and vascular endothelial dysfunction Atherosclerosis 138 2 1998 229 235
12. E.M. Bladbjerg, P. Marckmann, B. Sandstrom, and J. Jespersen Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet Thromb Haemost 71 6 1994 755 758
13. T. Atsumi, M.A. Khamashta, C. Andujar, M.J. Leandro, O. Amengual, and P.R. Ames Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome J Rheumatol 25 1 1998 69 73
14. N.M. Caplice, C. Panetta, T.E. Peterson, L.S. Kleppe, C.S. Mueske, and G.M. Kostner Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis Blood 98 10 2001 2980 2987
15. A. Cogo, E. Bernardi, P. Prandoni, B. Girolami, F. Noventa, and P. Simioni Acquired risk factors for deep-vein thrombosis in symptomatic outpatients Arch Intern Med 154 2 1994 164 168
16. G. Libertiny, and L. Hands Deep venous thrombosis in peripheral vascular disease Br J Surg 86 7 1999 907 910
17. P. Prandoni, F. Bilora, A. Marchiori, E. Bernardi, F. Petrobelli, and A.W. Lensing An association between atherosclerosis and venous thrombosis N Engl J Med 348 15 2003 1435 1441
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 8934 1994 1383 1389
19. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. MacFarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 20 1995 1301 1307
20. S.J. Lewis, L.A. Moye, F.M. Sacks, D.E. Johnstone, G. Timmis, and J. Mitchell Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 9 1998 681 689
21. A.M. Tonkin, D. Colquhoun, J. Emberson, W. Hague, A. Keech, and G. Lane Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study Lancet 356 9245 2000 1871 1875
22. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
23. R. Alonso, P. Mata, R. De Andres, B.P. Villacastin, J. Martinez-Gonzalez, and L. Badimon Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin Atherosclerosis 157 2 2001 423 429
24. T. Tsunekawa, T. Hayashi, H. Kano, D. Sumi, H. Matsui-Hirai, and N.K. Thakur Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days Circulation 104 4 2001 376 379
25. S. de Jongh, M.R. Lilien, J. op't Roodt, E.S. Stroes, H.D. Bakker, and J.J. Kastelein Early statin therapy restores endothelial function in children with familial hypercholesterolemia J Am Coll Cardiol 40 12 2002 2117 2121
26. S.H. Wilson, J. Herrmann, L.O. Lerman, D.R. Holmes Jr., C. Napoli, and E.L. Ritman Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering Circulation 105 4 2002 415 418
27. P.D. Thompson, N.M. Moyna, C.M. White, K.M. Weber, S. Giri, and D.D. Waters The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation Atherosclerosis 161 2 2002 301 306
28. L.P. Ma, D.N. Nie, S.X. Hsu, S.M. Yin, L.Z. Xu, and J.V. Nunes Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia J Assoc Acad Minor Phys 13 1 2002 23 26
29. L. Puccetti, A.L. Pasqui, M. Pastorelli, G. Bova, M. Cercignani, and A. Palazzuoli Time-dependent effect of statins on platelet function in hypercholesterolaemia Eur J Clin Invest 32 12 2002 901 908
30. A. Undas, K.E. Brummel, J. Musial, K.G. Mann, and A. Szczeklik Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation Circulation 103 18 2001 2248 2253
31. S. Colli, S. Eligini, M. Lalli, M. Camera, R. Paoletti, and E. Tremoli Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis Arterioscler Thromb Vasc Biol 17 2 1997 265 272
32. R. Baetta, M. Camera, C. Comparato, C. Altana, M.D. Ezekowitz, and E. Tremoli Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering Arterioscler Thromb Vasc Biol 22 4 2002 692 698
33. M. Camera, V. Toschi, C. Comparato, R. Baetta, F. Rossi, and M. Fuortes Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin Thromb Haemost 87 4 2002 748 755
34. N.B. Adams, P.L. Lutsey, A.R. Folsom, D.H. Herrington, C.T. Sibley, and N.A. Zakai Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis J Thromb Haemost 11 6 2013 1078 1084
35. M.A. Albert, E. Danielson, N. Rifai, and P.M. Ridker Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 1 2001 64 70
36. P.L. van Haelst, J.J. van Doormaal, J.F. May, R.O. Gans, H.J. Crijns, and J.W. Cohen Tervaert Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein Eur J Intern Med 12 6 2001 503 509
37. R.S. Rosenson, and C.C. Tangney Antiatherothrombotic properties of statins: implications for cardiovascular event reduction JAMA 279 20 1998 1643 1650
38. G. Dangas, D.A. Smith, A.H. Unger, J.H. Shao, P. Meraj, and C. Fier Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect Thromb Haemost 83 5 2000 688 692
39. I. Seljeflot, S. Tonstad, I. Hjermann, and H. Arnesen Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease Thromb Res 105 4 2002 285 290
40. D. Grady, N.K. Wenger, D. Herrington, S. Khan, C. Furberg, and D. Hunninghake Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study Ann Intern Med 132 9 2000 689 696
41. D.M. Herrington, E. Vittinghoff, F. Lin, J. Fong, F. Harris, and D. Hunninghake Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) Circulation 105 25 2002 2962 2967
42. J.G. Ray, M. Mamdani, R.T. Tsuyuki, D.R. Anderson, E.L. Yeo, and A. Laupacis Use of statins and the subsequent development of deep vein thrombosis Arch Intern Med 161 11 2001 1405 1410
43. C.J. Doggen, R.N. Lemaitre, N.L. Smith, S.R. Heckbert, and B.M. Psaty HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women J Thromb Haemost 2 5 2004 700 701
44. K. Lacut, E. Oger, G. Le Gal, F. Couturaud, S. Louis, and C. Leroyer Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study Fundam Clin Pharmacol 18 4 2004 477 482
45. C. Huerta, S. Johansson, M.A. Wallander, and L.A. Garcia Rodriguez Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom Arch Intern Med 167 9 2007 935 943
46. A.S. Ramcharan, K.J. Van Stralen, J.D. Snoep, A.K. Mantel-Teeuwisse, F.R. Rosendaal, and C.J. Doggen HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis J Thromb Haemost 7 4 2009 514 520
47. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 18 2009 1851 1861
48. H.T. Sorensen, E. Horvath-Puho, K.K. Sogaard, S. Christensen, S.P. Johnsen, and R.W. Thomsen Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study J Thromb Haemost 7 4 2009 521 528
49. V. Agarwal, O.J. Phung, V. Tongbram, A. Bhardwaj, and C.I. Coleman Statin use and the prevention of venous thromboembolism: a meta-analysis Int J Clin Pract 64 10 2010 1375 1383
50. A. Squizzato, M. Galli, E. Romualdi, F. Dentali, P.W. Kamphuisen, and L. Guasti Statins, fibrates, and venous thromboembolism: a meta-analysis Eur Heart J 31 10 2010 1248 1256
51. M. Pai, N.S. Evans, S.J. Shah, D. Green, D. Cook, and M.A. Crowther Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies Thromb Res 128 5 2011 422 430
52. L. Rabinowich, A. Steinvil, E. Leshem-Rubinow, S. Berliner, D. Zeltser, and O. Rogowski Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation Heart 98 24 2012 1817 1821
53. S. Biere-Rafi, B.A. Hutten, A. Squizzato, W. Ageno, P.C. Souverein, and A. de Boer Statin treatment and the risk of recurrent pulmonary embolism Eur Heart J 34 24 2013 1800 1806
54. C.D. Nguyen, C. Andersson, T.B. Jensen, A. Gjesing, A.M. Schjerning Olsen, and C. Malta Hansen Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study BMJ Open 3 11 2013 e003135
55. M. Schmidt, S.C. Cannegieter, S.A. Johannesdottir, O.M. Dekkers, E. Horvath-Puho, and H.T. Sorensen Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study J Thromb Haemost 12 8 2014 1207 1215
56. C.C. Yang, S.S. Jick, and H. Jick Statins and the risk of idiopathic venous thromboembolism Br J Clin Pharmacol 53 1 2002 101 105
57. L. Smeeth, I. Douglas, A.J. Hall, R. Hubbard, and S. Evans Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials Br J Clin Pharmacol 67 1 2009 99 109
58. J. Hippisley-Cox, and C. Coupland Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database BMJ 340 2010 c2197
59. D.J. Freeman, M. Robertson, E.A. Brown, A. Rumley, E.S. Tobias, and M. Frolich Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) BMC Geriatr 11 2011 8
60. A. Delluc, C. Tromeur, E. Le Moigne, E. Nowak, D. Mottier, and G. Le Gal Lipid lowering drugs and the risk of recurrent venous thromboembolism Thromb Res 130 6 2012 859 863
61. K. Rahimi, N. Bhala, P. Kamphuisen, J. Emberson, S. Biere-Rafi, and V. Krane Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials PLoS Med 9 9 2012 e1001310
62. Clofibrate and niacin in coronary heart disease JAMA 231 4 1975 360 381
63. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, and M.R. Taskinen Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 9500 2005 1849 1861
64. C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, and M. Silingardi Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 366 21 2012 1959 1967
65. T.A. Brighton, J.W. Eikelboom, K. Mann, R. Mister, A. Gallus, and P. Ockelford Low-dose aspirin for preventing recurrent venous thromboembolism N Engl J Med 367 21 2012 1979 1987
66. L.J. Melton III History of the Rochester Epidemiology Project Mayo Clin Proc 71 3 1996 266 274
67. M.D. Silverstein, J.A. Heit, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med 158 6 1998 585 593
68. J.A. Heit, S.A. Farmer, T.M. Petterson, K.R. Bailey, and I.I.I. Melton LJ Novel Risk Factors for Venous Thromboembolism (VTE): A Population-Based Case-control Study Blood 106 11 2005 1618
69. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 6 2000 809 815
70. J.A. Heit, C.L. Leibson, A.A. Ashrani, T.M. Petterson, K.R. Bailey, and L.J. Melton III Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study Arterioscler Thromb Vasc Biol 29 9 2009 1399 1405
71. M.K. Barsoum, J.A. Heit, A.A. Ashrani, C.L. Leibson, T.M. Petterson, and K.R. Bailey Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study Thromb Res 126 5 2010 373 378
72. L.T. Kurland, and C.A. Molgaard The patient record in epidemiology Sci Am 245 4 1981 54 63
73. J.L. St Sauver, B.R. Grossardt, B.P. Yawn, L.J. Melton III, and W.A. Rocca Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project Am J Epidemiol 173 9 2011 1059 1068
74. J.L. St Sauver, B.R. Grossardt, C.L. Leibson, B.P. Yawn, L.J. Melton III, and W.A. Rocca Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project Mayo Clin Proc 87 2 2012 151 160